To test the relative efficacies of aspirin and dipyridamole in the reduction of cerebral and retinal infarction or death in patients with a history of TIA.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Dipyridamole (Persantine®)Drug
Intervention Desc: Platelet aggregation inhibitor
Double-blind, randomized, cooperative trial of 890 patients at 15 centers in the U.S. and Canada.
Patients were randomized to receive either aspirin (325 mg) plus placebo four times daily or aspirin (325 mg) plus dipyridamole (75 mg) four times daily. The decision to continue or discontinue the study medications was left to the attending physician. Follow-up visits were scheduled to take place every three months beginning one month after randomization. Median total follow-up time was 25 months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Stroke, retinal infarction, or death from any cause.|
|Secondary||Subgroup analyses, deaths, adverse events.|